Noticias de REVB_US

Noticias del mercado

Últimas noticias sobre REVB_US — 73 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: REVB_US ✕ 73 resultados
07/05/2026 REVB_US — MarketScreener
Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05/2026 REVB_US — geneonline.com
Revelation Biosciences Inc. Announces First Quarter 2026 Financial Results Ending March 31

Revelation Biosciences Inc. publicó su resultado financiero […]

07/05/2026 REVB_US — Stock Titan
FDA agrees to single Gemini study for acute kidney injury
07/05/2026 REVB_US — Stock Titan
Q1 2026 results for Revelation Biosciences (NASDAQ: REVB) detailed
07/05/2026 REVB_US — Stock Titan
Revelation Biosciences (REVB) Q1 loss widens as cash runway and going concern risks emerge
04/05/2026 REVB_US — TradingView
Revelation Biosciences Inc expected to post a loss of $1.15 a share - Earnings Preview
01/05/2026 REVB_US — Stock Titan
Revelation Biosciences (REVB) CFO reports tax-withholding share sale via trust
01/05/2026 REVB_US — Stock Titan
Revelation Biosciences (REVB) CEO has shares sold to cover tax withholding
30/04/2026 REVB_US — Stock Titan
Revelation Biosciences (NASDAQ: REVB) asks shareholders to approve wide reverse split
25/04/2026 REVB_US — The Sheboygan Press ES ← EN
Revelation Biosciences anuncia el inicio de la fabricación GMP de GEMINI y placebo para respaldar el desarrollo clínico en etapas posteriores

SAN DIEGO, CA / ACCESS Newswire / 7 de enero de 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (la "Compañía" o

22/04/2026 REVB_US — haiphong.gov.vn
REVB (Revelation Biosciences Inc.) falls 4.58% today after Q4 2025 EPS misses estimates by a staggering 541.5%.
22/04/2026 REVB_US — sonla.gov.vn
REVB (Revelation Biosciences Inc.) posts drastically wider than expected Q4 2025 loss, sending its stock down 4.76% in today’s trading. - EBITDA Margin
18/04/2026 REVB_US — Newser
REVB (Revelation Biosciences Inc.) falls 4.58% today after Q4 2025 EPS misses estimates by a staggering 541.5%.
18/04/2026 REVB_US — newser.com
REVB (Revelation Biosciences Inc.) falls 4.58% today after Q4 2025 EPS misses estimates by a staggering 541.5%.
18/04/2026 REVB_US — newser.com
REVB (Revelation Biosciences Inc.) falls 4.58% today after Q4 2025 EPS misses estimates by a staggering 541.5%. - Hedge Fund Inspired Picks
18/04/2026 REVB_US — newser.com
REVB (Revelation Biosciences Inc.) falls 4.58% today after Q4 2025 EPS misses estimates by a staggering 541.5%.
18/04/2026 REVB_US — newser.com
REVB (Revelation Biosciences Inc.) falls 4.58% today after Q4 2025 EPS misses estimates by a staggering 541.5%. - ROE
16/04/2026 REVB_US — newser.com
REVB (Revelation Biosciences Inc.) posts drastically wider than expected Q4 2025 loss, sending its stock down 4.76% in today’s trading. - ROE
16/04/2026 REVB_US — newser.com
REVB (Revelation Biosciences Inc.) posts drastically wider than expected Q4 2025 loss, sending its stock down 4.76% in today’s trading. - EPS Growth
16/04/2026 REVB_US — newser.com
REVB (Revelation Biosciences Inc.) posts drastically wider than expected Q4 2025 loss, sending its stock down 4.76% in today’s trading. - AI Powered Stock Picks

Página 2 de 4

keyboard_arrow_up